Indian High Commission & INZBC Launches white paper on Pharma Landscape in New Zealand
India New Zealand Business Council and the Indian High Commission are proud to present to you our latest publication on the Health and Pharmaceutical Landscape of New Zealand.
This report emerged out of many conversations from our event late last year, held in the midst of a growing need for collaborations between countries to put an end to a pandemic unlike any our generation had ever seen.
Thankfully, we are now in a much better position in recovering from this crisis. It is a testament to the incredible resilience everyone has collectively shown in the face of a crisis like a few others.
In the year 2021, New Zealand imported NZ$ 91.03 million of pharmaceutical products from India, representing 2.3% of total imports of pharmaceutical products. There is a huge potential for growth in bilateral trade in the pharmaceutical sector considering the fact that India enjoys an important position in the global supply.
India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of the global demand for various vaccines. Globally, India ranks 3rd in terms of pharmaceutical production by volume and 14th by value.
This manual is a sincere effort to put together relevant details
relating to steps to be taken for exporting medicines to New Zealand and listing of relevant organisations.
The report also gives important contact details of key stakeholders in New Zealand.
This publication is an all-in-one guide for all stakeholders in the Pharma sector in India who desire to trade with New Zealand.
Download Report:
Health & Pharmaceutical Landscape for New Zealand, a roadmap for Indian Pharma Companies.
March 2022 Edition
Commissioned by: High Commission of India, New Zealand
Research & Published by: India New Zealand Business Council.
